Cerebel - EGF111438
Laufzeit: 01.01.2009 - 31.12.2012
Kurzfassung
A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer
